CD8A and neoplasm: The IMpassion130 study assessed the efficacy of atezolizumab in combination with nab-paclitaxel for advanced TNBC patients, with its exploratory analysis revealing that CD8 + T cell infiltration in the tumor microenvironment could serve as a predictive biomarker for OS benefits from atezolizumab treatment in metastatic TNBC cases.